Overview

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
Phase:
Phase 1
Details
Lead Sponsor:
Aerie Pharmaceuticals